Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Select Medical Holdings Corporation filed an SEC 8-K exhibit containing an execution version agreement and plan of merger dated March 2, 2026. The agreement is by and among Stallion Intermediate Corporation, Stallion MergerSub Corporation, and Select Medical Holdings Corporation.
The document covers merger structure, closing and effective time, surviving corporation governance, exchange of eligible shares and delivery of merger consideration, and treatment of equity awards. It also includes interim operating covenants, closing conditions, and termination provisions.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026